Legend Strat <1355> completion announcement disclosable transaction the purchase of in relation shares in to Auro Hong Kong
TL;DR
Legend Strategy International Holdings Group (1355.HK) announces completion of a HK$22 million acquisition of shares in Auro Hong Kong Limited, funded by interest-free borrowings from its largest shareholder. The target, Beisheng Biotechnology Group, focuses on DNA/strain manufacturing and bioinformatics, with revenue fluctuations and a strategic pivot toward a 2026 commercial launch. The transaction is conditional, and post-completion, Legend Strategy will appoint two directors to oversee operations, emphasizing integration and future commercialization success.
Tags
Legend Strat <1355> completion announcement disclosable transaction the purchase of in relation shares in to Auro Hong Kong
Legend Strategy International Holdings Group (1355.HK) has issued a supplemental announcement regarding its discloseable acquisition of shares in Auro Hong Kong Limited, a transaction initially disclosed earlier this year. The acquisition, valued at HK$22 million, is funded entirely through interest-free borrowings from Osibao Cosmetics International Limited, the company's largest shareholder, which holds 28.99% of the shares. No further funding obligations exist for the group at this stage.
The target asset, Beisheng Biotechnology Group, operates as an integrated platform offering DNA/strain manufacturing, bioinformatics software (Tosycon®), and proprietary bio-manufacturing solutions (ArchiCel®). Its business model emphasizes cost reduction and process efficiency for clients in agriculture, biotechnology, and laboratory services. Financially, Beisheng reported RMB 1.81 million in revenue for 2023, rising to RMB 3.95 million in 2024, though revenue for the first 11 months of 2025 declined to RMB 487,000, reflecting a strategic pivot toward product refinement ahead of a 2026 commercial launch.
The acquisition remains conditional on fulfilling stipulated terms in the Sale and Purchase Agreement. Post-completion, Legend Strategy will appoint two directors to Beisheng's five-member board, ensuring operational oversight. Management highlights the team's expertise in R&D and production, with integration plans focused on aligning biotechnology capabilities with the group's existing portfolio.
Shareholders are cautioned to consider the transaction's conditional nature and potential share price volatility. The company emphasizes that future performance hinges on successful commercialization of Beisheng's platforms in 2026.
